References
- Gattermann N, Billiet J, Kronenwett R, et al. High frequency of the JAK2V617F mutation in patients with thrombocytosis (platelet count 600 109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood 2007;109:1334–1335.
- Schnittger S, Bacher U, Haferlach C, et al. Detecion of an MPLW515 mutation in a case with features of both essential thrombocythemia and refactory anemia with ringed sideroblasts and thrombocytosis. Leukemia 2008;22:453–455.
- Russell M, List A, Greenberg P, et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 1994;84:1243–1248.
- Cilloni D, Gottardi E, Messa F, et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 2003;21:1988–1995.
- Shaw GR. Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol 2005;131:180–184.
- Huls G, Mulder AB, Rosati S, et al. Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. Blood 2010; 116:180–182.
- Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003;101:837–845.
- Willasch AM, Gruhn B, Coliva T, et al. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Leukemia 2009;23:1472–1479.
- Speletas M, Katodritou E, Daiou C, et al. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. Leuk Res 2007;31:1053–1062.
- Ruan GR, Jiang B, Li LD, et al. MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ- PCR based on TaqMan MGB probes. Hematol Oncol 2010;28: 33–39.
- Gilliland DG. Hematologic malignancies. Curr Opin Hematol 2001;8:189–191.
- Trubia M, Albano F, Cavazzini F, et al. Characterization of a recurrent translocation t(2;3)(p15-22;q26) occurring in acute myeloid leukemia. Leukemia 2006;20:48–54.
- Stevens-Kroef M, Poppe B, van Zelderen-Bhola S, et al. Translocation t(2;3)(p15-23;q26-27) in myeloid malignacies: report of 21 new cases, clinical, cytogentic and molecular genetic features. Leukemia 2004;18:1108–1114.
- Balgobind BV, Lugthart S, Hollink IH, et al. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia 2010;24:942–949.
- Shackelford D, Kenific C, Blusztajn A, et al. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. Cancer Res 2006;66:11360–11369.